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Abstract
Prostate cancer is the most common visceral malignancy in Western men and a major cause of cancer deaths. Increased
activation of the AKT and NFkB pathways have been identified as critical steps in prostate cancer initiation and progression.
GGAP2 (GTP-binding and GTPase activating protein 2) is a multidomain protein that contains an N-terminal Ras homology
domain (GTPase), followed by a PH domain, a C-terminal GAP domain and an ankyrin repeat domain. GGAP2 can directly
activate signaling via both the AKT and NFkB pathways and acts as a node of crosstalk between these pathways. Increased
GGAP2 expression is present in three quarters of prostate cancers. Mutations of GGAP2 have been reported in cell lines from
other malignancies. We therefore analyzed 84 prostate cancer tissues and 43 benign prostate tissues for somatic mutations
in GGAP2 by direct sequencing of individual clones derived from the GAP and GTPase domains of normal and tumor tissue.
Overall, half of cancers contained mutant GAP domain clones and in 20% of cancers, 30% or more of clones were mutant in
the GAP domain. Surprisingly, the mutations were heterogeneous and nonclonal, with multiple different mutations being
present in many tumors. Similar findings were observed in the analysis of the GTPase domain. Mutant GGAP2 proteins had
significantly higher transcriptional activity using AP-1 responsive reporter constructs when compared to wild-type protein.
Furthermore, the presence of these mutations was associated with aggressive clinical behavior. The presence of high
frequency nonclonal mutations of a single gene is novel and represents a new mode of genetic alteration that can promote
tumor progression. Analysis of mutations in cancer has been used to predict outcome and guide therapeutic target
identification but such analysis has focused on clonal mutations. Our studies indicate that in some cases high frequency
nonclonal mutations may need to be assessed as well.
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Introduction
A variety of genetic and epigenetic alterations have been
described in prostate cancer. Numerous studies have found
consistent patterns of copy number alterations such as loss of 8p
and 13q14 and gain of 8q24 in clinically localized and advanced
prostate cancers [1,2]. Epigenetic alterations such as methylation
are also common in prostate cancer. In contrast, most studies to
date have shown only infrequent clonal point mutations in
clinically localized prostate cancer [2,3]. In more advanced
prostate cancers, clonal point mutations of tumor suppressor
genes such as PTEN [4] and p53 [3] are more common, in
contrast to the low frequency of mutation of these genes in
localized cancer [5,6], but are still not common compared to most
malignancies. Activating clonal mutations in oncogenes, such as
RAS, are not common in prostate cancer in the US [3], in contrast
to the more frequent mutation observed in other common human
cancers such as colon and lung cancer. Clonal androgen receptor
mutations are seen in castrate resistant prostate cancer and appear
to be selected for as a mechanism by which prostate cancer cells
can survive in low androgen environment [3]. Thus available data
indicate that clonal point mutations, particularly of oncogenes, are
rare in clinically localized prostate cancer.
GGAP2 (also known as PIKE-A) is a G-protein which has a
strong GTPase activity, as expected from its RAS homology
domain. It also contains a GAP domain can activate the GTPase
activity via either intramolecular or intermolecular interaction.
GGAP2 binds to activated AKT and strongly enhances its activity
and this interaction is promoted by GTP binding [7]. We have
shown that activated AKT can bind and phosphorylate GGAP2 at
serine 629, which enhances GTP binding by GGAP2 and AKT
activation [8]. Phosphorylated GGAP2 can also bind the p50
subunit of NFkB and enhances NFkB transcriptional activity.
Increased activation of the phosphatidyl-inositol-3 kinase/AKT
and NFkB pathways have both been identified as critical pathways
in cancer initiation and progression in a variety of human
malignancies, including prostate cancer. We have demonstrated
significantly increased expression GGAP2 in the majority of
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prostate cancer cells it enhances proliferation, focus formation in
vitro and tumor progression in vivo. Thus increased GGAP2
expression, which is present in three quarters of human prostate
cancers, can activate two critical pathways that have been linked to
prostate cancer initiation and progression and can enhance tumor
progression in vivo.
Hu et al have identified mutant forms of GGAP2 in sarcoma,
neuroblastoma and glioblastoma cell lines [9]. In vitro studies
show these mutant forms have enhanced GTPase activity and
more strongly activate AKT than wild-type GGAP2. Consistent
with these observations the GGAP2 mutants promote growth of
glioblastoma cells and transformation of NIH3T3 cells [10]. We
therefore sought to identify mutations of GGAP2 in human
prostate cancer samples. We have found high frequencies of
missense GGAP2 mutations in clinically localized human prostate
cancer. Surprisingly, the mutations are heterogeneous and
nonclonal, with multiple different mutations being present in
many tumors. The presence of these mutations was associated with
aggressive clinical behavior and increased AP-1 transcriptional
activity. Thus, GGAP2 is the most commonly mutated oncogene
in human prostate cancer to date but the mutations are
heterogeneous rather than clonal, implying marked clonal
heterogeneity in clinically localized human prostate cancers. The
presence of high frequency nonclonal mutations of a single gene is
novel and represents a new mode of genetic alteration that can
promote tumor progression.
Results
Mutation analysis of the GAP domain of GGAP2
To determine if GGAP2 is mutated in prostate cancer we
initially focused on the GAP domain, since this region is an
important negative regulator of GGAP2 activity. We analyzed
cDNAs from 15 cancers and 9 benign prostate tissues from radical
prostatectomy specimens. The GAP domain was amplified and
individual clones were isolated and sequenced. Results are shown
in Table 1. Twelve of fifteen cancer cases had at least one clone
with a GGAP2 missense and/or stop mutations while only 2 of 9
benign cases had such mutations. The benign cases had only a
single mutant clone each while up to 42 percent of clones in the
cancer cases were mutated. Overall 38 of 206 clones from the
cancer tissues were mutant versus 2 of 137 in benign. This
difference was highly statistically significant (p,0.001, chi square).
To rule out an artifact due to reverse transcription or the
possibility that mutant transcripts may be transcribed preferen-
tially or have increased stability we directly analyzed the GAP
domain in genomic DNAs from 46 cancers and 22 benign tissues.
As shown in Table 1, 20 of 46 cancer tissues contained at least one
mutant clone and in 12 of 46 cancer tissues more than 30% of
clones contained missense or stop mutations. Only a single mutant
clone was identified from the benign tissues. Overall, 52 of 334
clones from the cancer tissues were mutant versus 1 of 167 from
the benign tissues (p,0.001, chi square). Combining cDNA and
genomic analysis, 32 of 61 cancer cases contained clones with
GAP domain mutations and in 14 cases 30% or more of the clones
were mutant.
Surprisingly we found that the missense mutations were highly
heterogeneous. There were no recurrent missense mutations
involving more than two tumors. In tissues with multiple mutant
clones there were only two cases with two identical mutant clones.
There was variability in the distribution of the missense mutations
with the regions between amino acids 640–660 and 700–710
having relatively more frequent mutations while mutations were
uncommon from amino acids 540–570 but there was no
statistically significant ‘‘hot spots’’. In several clones we found 2
mutations in the same clone. This is similar to the observation of
Hu et al [9], who found multiple mutations in several mutant
GGAP2 cDNAs isolated from sarcoma and glioblastoma cell lines.
In addition to the multiple missense mutations, we observed 3 stop
mutations, all at the carboxy terminal portion of the GAP domain
(aa 703–709) which is located toward the carboxy terminus of the
GGAP2 protein and would result in a truncated protein. Of note,
Hu et al [9] found a truncation at amino acid 756 in the GGAP2
cDNA from CRL-2098 osteosarcoma cells.
Given this surprising heterogeneity we considered the possibility
that this may represent a PCR misincorporation artifact.
However, we found only 3 silent mutations among 540 clones
from cancer tissues (versus 90 missense or stop) while in the benign
tissues we found 2 silent mutations among 304 clones (versus 3
missense mutations). The proportion of missense and stop versus
silent mutation was much higher in the cancer tissue than in the
benign tissue and the difference was statistically significant
(p=0.02, Fisher exact test). This is inconsistent with a random
misincorporation. To further examine this point, we systematically
determined the consequences of transition mutations on amino
acid sequence for all nucleotides in the GAP domain. We only
examined transitions since 82% of the observed mutations were
transition mutations (data not shown). Systematic transition
mutation of each nucleotide in the GAP domain would yield
273 missense, 15 stop mutations and 162 silent mutations. The
difference in the proportions of missense and stop versus silent
mutations we observed (90 and 3) compared the predicted
distribution (288 and 167) was highly statistically significant
(p,0.001, chi sq). Finally, we considered the possibility that the
cancer tissues had an increase rate of mutation targeting the first
and second bases of each codon resulting in random missense
mutation in all genes. We therefore examined 5 cancer and 5
benign tissues for mutations in b-actin. We found no mutations in
32 clones from cancer tissue and 36 clones from benign tissues.
The proportion of missense and stop clones in GGAP2 was
statistically significantly higher than in b-actin (p=0.02, chi sq).
Thus the observed heterogeneous mutations in the GAP domain
of GGAP2 are indeed genuine.
Mutation analysis of the GTPase domain of GGAP2
The GTPase domain is also a key regulator of GGAP2 activity.
We therefore examined cDNAs from 23 cancers and 12 benign
tissues for GTPase domain mutations. The results were very
similar to those observed with GAP domain (Table 2). Fifteen of
23 cancers contained missense mutations versus 1 of 12 benign
tissues. In four cancer cases, 40% or more of clones were mutant,
while only a single mutant clone was observed in the benign tissue.
Overall, 28 of 188 clones from the cancer tissues were mutated
versus 1 of 88 in benign tissue (p,0.001, chi sq). The overall
pattern of mutations in the cancer tissue was similar to the GAP
domain in that mutations were highly heterogeneous, both within
a single cancer tissue and between cancer tissues. We found one
double mutant clone, similar to the GAP domain. Of note, no stop
mutations were observed. Given the amino terminal location of
the GTPase domain, any stop mutations would almost certainly
yield inactive protein since it would lack the PH domain. We
found only 2 silent mutations, one in a cancer and one from
benign tissue. In nine tissues of 35 analyzed (26%) we detected
multiple clones containing a previously described silent polymor-
phism (Rs17852479) at L246 which does not result in any amino
acid change. This polymorphism occurs in approximately 28% of
individuals in previously studied populations, similar to our
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in Table 3.
GAP Domain Mutations Increase AP-1 Transcriptional
Activity
We have shown that NFkB can increase expression of FOS in
prostate cancer cells and thus AP-1 activity [11]. To test whether
GGAP2 and mutant GGAP2 impacted AP-1 transcription we used
site directed mutagenesis to engineer GGAP2 expression constructs
containing 9 different missense mutations. These mutant constructs
orwild-typeoremptyvectorcontrolswereco-transfectedwithanAP-
1 reporter construct into 293T cells and normalized luciferase activity
measured. As shown in Figure 1, wild type GGAP2 modestly
increases AP-1 driven transcription. Multiple mutant clones demon-
strated marked enhancement of AP-1 promoter transcription in cells
transfectedwithmutantwhencomparedtowild-typeGGAP2(Fig.1).
Table 1. Mutation analysis of the GAP domain of GGAP2 in prostate cancer.
cDNA Missense Stop
ID Type Clones Mutations Percent
7357 Cancer 19 8 42 E656G V711M I589F S584A
L624P E696G L630P W703X
1954 17 5 29 L624M E672G L643P S705T
AS692G
11686 20 4 20 S666P/K681E N648S G594R/L632W
10420 12 4 33 R653C A705G R679H V711M
11147 14 3 21 D649G I678T T640A
9523 18 3 17 G621D G594E A580V/A607T
6882 14 3 21 L641P A645D Q709X
6098 7 2 29 D710V L702P
6511 10 2 20 R662C T622I
3689 12 2 17 T599P L686P
8032 13 1 8 C593R
12375 13 1 8 L698P
97 Benign 16 1 6 S670P
11627 16 1 6 L620V
Genomic
19334 Cancer 8 5 63 E638G W600R I611V E612K
A721V
27312 8 4 50 A663P Q707R I581V V576A
11537 9 4 44 D633G Q684R S625P A651G
23536 10 4 40 N648Y V591L G586R Q707R
47974 9 4 44 E612V V642G I646L L639M
17557 6 3 50 K664Q I609T G621C
6337 7 3 43 T659A I609T A651G
20088 7 3 43 S657G V706M I611V
17125 8 3 38 I581V R582P I581V
18099 10 3 30 K664Q H623R A607V/E696G
22766 10 3 30 E612Q G621S S602N
18062 10 3 30 S692G T569A A544T
10702 7 2 29 Y682C Q707R
21918 8 2 25 A708V A708V
8665 10 1 10 W600L/S629L
27804 8 1 12 N652I/L686P
29823 8 1 12 R653C
26065 6 1 17 S629P
24069 10 1 10 D592G
29886 10 1 10 Q707X
25909 Benign 9 1 11 T659A
Missense and stop mutations cancer and benign tissues are shown using the format: normal amino acid/amino acid number in GGAP2/mutant amino acid. An X
indicates a stop mutation. Only tissues with missense or stop mutations are shown.
doi:10.1371/journal.pone.0032708.t001
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pathological parameters of aggressive disease
To determine whether the presence of missense or stop
mutations in the GAP domain were associated with aggressive
disease we examined in proportion of such mutant clones in
prostate cancers with various clinical and pathological parameters
associated with aggressive disease (Figure 2). Early PSA recurrence
after radical prostatectomy is associated with death from disease
[12]. Cancers with early PSA recurrence had 49 mutations among
172 clones analyzed, while cases without early PSA recurrence had
only 34 mutations in 234 clones. This difference was statistically
significant (p,0.001, chi sq). Consistent with this, we also found
significantly increased proportions of GAP mutations in cases with
pelvic lymph node metastasis (p=0.027, chi sq), seminal vesicle
invasion (p=0.027, chi sq), extracapsular extension (p=0.015, chi
sq) and higher Gleason score (Gleason 5/6 Versus 7–10,
p=0.002, chi sq). These findings strongly support the concept
that GAP domain mutations in GGAP2 can promote prostate
cancer progression.
Discussion
Clonal mutations in clinically localized prostate cancer are
uncommon and usually involve tumor suppressor genes (reviewed
in [3]). Mutations in oncogenes such as RAS are uncommon in US
men with prostate cancer although RAS mutations have been
identified more commonly in prostate cancers from Japanese men
[3]. We have identified frequent mutations of GGAP2 in localized
prostate cancer. Overall, half of cancers contained at least one
mutant GAP domain clone and in 20% of cancers, 30% or more
of clones were mutant in the GAP domain. Surprisingly, while
there were 10 different recurrent mutations these only recurred 2–
3 times each, overall the GAP domain mutations were
heterogeneous and nonclonal. Similar findings were observed in
the analysis of the GTPase domain. Multiple lines of evidence
Table 2. Mutation analysis of the GTPase domain of GGAP2 in prostate cancer.
ID Tissue Clones Mutations Percent Missense mutations
10764 Cancer 9 4 44 V364A L239P P300S R182G
6346 10 4 40 E281G S275P A198V S302P
12161 10 4 40 A173T N265D E167K H117R
4343 5 2 40 Q115R L246F
8032 9 2 22 H268R/L234P Q262R
7357 10 2 20 R234C S329N
8748 8 2 25 S207N C200G
1954 8 1 12 E332G
3230 7 1 14 K360E
3689 8 1 12 R310G
6882 10 1 10 A292V
9560 7 1 14 S329G
11147 6 1 17 F223L
14198 7 1 14 A175T
15250 7 1 14 K229E
1610 Benign 12 1 8 H117R
The GTPase domain was cloned from cDNAs from prostate cancer (.70% cancer) or benign peripheral zone tissues and sequenced. A total of 23 cancers and 12 benign
tissue samples were analyzed. The number of clones is indicated as is the number and percentage of clones with missense mutations. For each individual tissue the
missense mutations are shown using the format: normal amino acid/amino acid number in GGAP2/mutant amino acid. Only tissues with missense mutations are shown.
doi:10.1371/journal.pone.0032708.t002
Table 3. Summary of mutation analysis of GAP and GTPase.
Tissue DNA Analyzed Number of Tissues Total Clones Missense/Stop Silent
Cancer GAP (cDNA) 15 206 38 2
GAP (genomic) 46 334 52 1
GTPase (cDNA) 23 188 28 1
DNA Analyzed Number of Tissues Total Clones Missense/Stop Silent
Benign GAP (cDNA) 9 137 2 2
GAP (genomic) 22 167 1 0
GTPase (cDNA) 12 88 1 1
Summary of mutation analysis of GAP and GTPase clones from cDNA or genomic DNAs from prostate cancer or benign prostate tissues. Does not include the known
germline polymorphic loci.
doi:10.1371/journal.pone.0032708.t003
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mutation in benign prostate tissues; the dominance of missense
mutations in the cancer tissues; the paucity of silent mutations in
cancer tissues and the absence of mutations in b-actin.
While both overexpression and nonclonal mutation of GGAP2
are common in prostate cancer the relationship between these two
alterations is unclear. Both can potentially activate the siganaling
activities of GGAP2 in prostate cancer, although detailed studies
would be needed to discern whether these activities are the same
for different specific mutations. In some cases overexpression
might potentially enhance the biological activities associated with
mutation although it is also possible that mutation may
compensate for lack of overexpression. Detailed studies of GGAP2
expression, nonclonal mutation and markers of pathway activation
Figure 1. GGAP2 mutations result in enhanced transcription from AP-1 reporter constructs. Asterisks indicate statistically significant
increase relative to wild-type (WT) GGAP2 by ANOVA (p,.05). Mean +/2SEM. Mutation and number of transfections are shown.
doi:10.1371/journal.pone.0032708.g001
Figure 2. Association of GAP domain mutations with clinical and pathological parameters associated with aggressive prostate
cancer. The fraction of clones containing missense or stop mutations for cases with each indicated clinical or pathological parameter is shown. All
differences between pathological and clinical variables were statistically significant. Specifically: for early PSA recurrence (,2 years post surgery)
versus no or late recurrence (p,0.001, chi sq); extracapsular extension (ECE) versus no ECE (p=0.015, chi sq); seminal vesicle invasion (SVI) versus no
SVI (p=0.027, chi sq); pelvic lymph node metastasis (LN) versus no metastasis (p=0.027, chi sq); Gleason 5/6 versus 7–10 (p=0.002, chi sq).
doi:10.1371/journal.pone.0032708.g002
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impact of these distinct alterations in prostate cancer.
Intratumoral genetic heterogeneity involving point mutations of
genes such as p53 or K-RAS in different regions of single
macroscopic tumors has been noted in cancers such as colon
cancer [13] and gliomas [14]. It should be noted that in our cases
all tumors represent a single 6 mm tumor focus and thus our
cancers all were from a single tumor focus and is thus the
heterogeneity we observed is distinct from this geographic genetic
heterogeneity. In our case, the observed heterogeneity reflects
heterogeneity at the cellular level within a single tumor focus.
Are the mutations we observed significant? The missense
mutation frequency observed in the GAP domain in cancer tissues
was 370610
26 per bp sequenced and for the GTPase domain
298610
26 per bp. Bielas et al [15] have shown that the frequency
of random mutation in cancer tissues is approximately 2.1610
26
per bp across multiple cancer types. Thus our observed frequency
for missense mutation in GGAP2 is 100-fold higher than the
background rate of mutation, strongly implying selective growth
advantage for the mutant clones. We have also found a significant
association between the frequency of mutation in the GAP domain
and clinical and pathological parameters associated with aggres-
sive disease, indicating they are clinically significant. It should be
noted that in 20% of cases examined that more than 30% of clones
from cancer were mutant in the GAP domain. Given that the
tissues analyzed were approximately 80% cancer on average, at
least 75% of cancer cells would contain a mutant allele (assuming
one mutation per cell) in such cases. This is a minimum figure
since it does not include GTPase domain mutations and potential
mutations in other regions of GGAP2, which have been reported
[9]. Thus the observed high frequency heterogeneous mutations
could contribute directly to local tumor growth in many cases. In
addition, the most potent mutations may promote metastasis of
specific cellular clones. There is evidence to support the concept
that nonclonal p53 mutations in primary prostate cancers can give
rise to metastatic lesions [16]. The high frequency of diverse
nonclonal mutations in GGAP2 may provide numerous potential
metastatic clones.
Most studies of mutations in cancer have justifiably focused on
clonal mutations since it is easier to see the significance of such
mutations. Heterogeneous nonclonal mutations will not be
detected by many analytical methods or are not further analyzed
since it is unclear whether they may be PCR artifacts or simply
passenger mutations. Our findings indicate that in some cases high
frequency heterogeneous nonclonal mutations can occur and may
be clinically important. It remains to be determined how often this
is the case with other tumor suppressor genes and oncogenes. In
some cases groups have analyzed primary prostate cancers for the
presence of mutation using single stranded conformation poly-
morphism assays followed by sequencing of abnormally migrating
bands and found relatively high rates of mutation in some genes.
For example, using this approach, mutations in plexin-B1 in were
identified in 46% of primary prostate cancers [17] but it is difficult
to determine the exact percentage of tumor cells in a tumor with
that mutation. Given that the mutations are frequent enough to
give a distinct band on single stranded conformation polymor-
phism assays they must be quite frequent although not clonal. This
is in contrast to our findings in GGAP2 in which the mutations are
highly heterogeneous. Thus variable levels of nonclonal mutations,
from highly heterogeneous to oligoclonal may exist in prostate
cancer. On the other hand, using an approach similar to ours,
Steinkamp et al [18] sequenced androgen receptor mRNAs from
castrate resistant prostate cancer metastasis. They found high
levels of heterogeneity in the mutations with many mutations
being present in only 5–10% of clones. This finding is similar to
what we observed in GGAP2. The androgen receptor plays a
central role in prostate cancer pathogenesis and survival so there is
strong selective pressure to retain mutations that lead to activity in
the face of anti-androgen therapies. We have shown that GGAP2
is frequently overexpressed in prostate cancer and can activate two
key pathways in prostate cancer progression i.e. the NFkB and
AKT pathways. In addition, it has a relatively large negative
regulatory domain that may be susceptible to disruption, which
may make it far easier to activate than some oncogenes such as
RAS that require specific point mutations. Additional analyses will
be needed to determine the extent to which other genes, including
tumor suppressor genes and other oncogenes, have high frequency
non-clonal missense or stop mutations.
The potential for high frequency nonclonal mutation adds
another layer of complexity to the complex mutational landscape
of common cancers that has been revealed by large scale
sequencing [19,20,21]. Of note, it has been shown that nonclonal
mutations in K-RAS in lung cancer treated with tyrosine kinase
inhibitors significantly impact survival [22]. Thus it will be
important to determine the extent to which nonclonal mutations
occur across of broad range of genes in prostate and other cancers
and whether they impact survival and response to therapy.
Materials and Methods
Human tissue samples
Normal peripheral zone and cancer tissues were collected with
written informed consent from men undergoing radical prosta-
tectomy by the Baylor College of Medicine Prostate Cancer
Program Tissue Bank and snap frozen as described previously
[23]. Patients ranged in age from 43–73 years of age and were
predominantly Caucasian. In all cases preoperative imaging and
clinical examination revealed clinically localized disease. Patho-
logical staging of radical prostatectomy specimens and pelvic
lymph nodes showed approximately 30% Stage 2 (T2N0); 50%
Stage 3 (T3N0) and 20% Stage 4 (Any T, N1). All patients
provided written informed consent to donate tissues for research
and these studies were approved by the Baylor College of
Medicine Institutional Review Board. Benign tissues were
confirmed to be free of cancer and cancer tissues contained at
least 70% carcinoma. RNAs and DNAs were extracted as
described previously [24,25]. PSA recurrence was defined as
serum PSA.0.2 ng/ml, with early recurrence being recurrence
within 2 years of surgery.
Mutation analysis
The N-terminal GTPase domain and the C-terminal GAP
domain of GGAP2 gene were amplified using PCR and cloned
into the PCR 2.1 TOPO vector using TOPO TA cloning kit (
Invitrogen). PCR was performed using Platinum Taq (Invitrogen)
to minimize misincorporation. Primers used for cloning were: for
GTPase domain Forward: CCGCTCCATTCCTGAACTG;
Reverse: GTTGCTGCTTGCGCAAG for the GAP domain:
Forward: CACAGACAGCCAAAGCGA; Reverse: CCAAAAG-
CAGGAGAACGGTAG. DNAs were sequenced in both direc-
tions and all base pair changes called by the machine read of the
sequence were confirmed by visual examination of sequencing
traces. Clones with poor quality sequencing traces were not
analyzed. No novel reportable germ line variants were detected.
Site directed mutagenesis
Single nucleotide mutagenesis was carried out according to the
manufacturer’s protocol (Stratagene). Briefly, primers with the
GGAP2 Mutations in Prostate Cancer
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constructs containing 9 different missense mutations. Primers used
are shown in Table 4. Dpn1enzyme was added to PCR products
for 1 h at 37uC to digest template plasmid DNA before the
transformation. Clones were sequenced to verify the mutations.
Luciferase transcriptional reporter assays
Luciferase transcriptional reporter assays were performed as
described previously [11] using 293T cells. Both AP-1 luciferase
reporter vector and pRL Renilla Luciferase vector were obtained
from Stratagene (Cat# 219077 and #E2810). The pRL Renilla
Luciferase Reporter Vectors are intended for use as an internal
control reporters in combination with AP-1 to cotransfect 293T
cells. Transient transfection was conducted in triplicate in 24-well
plates. Luciferase activity was determined and normalized to
Renilla luciferase signal for each sample. Independent assays were
performed from 3–9 times.
Statistical analysis
To compare rates of mutation between groups chi square or
Fisher exact analysis was performed. Luciferase activity of mutant
clones was compared using analysis of variance (ANOVA). For all
tests p,.05 was considered significant.
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Table 4. Primers for site directed mutagenesis of GGAP2.
L233S For GAAGGTGGTGACCTCGCGCAAGCAGCAACA
Rev TGTTGCTGCTTGCGCGAGGTCACCACCTTC
S275P For CGACTACTCTTCTCCCCTCCCGTCCTCACC
Rev GGTGAGGACGGGAGGGGAGAAGAGTAGTCG
L239P For GCCTCTGGCTGCCTGCAAGTCCCTGC
Rev CCAGAGGCTGTTGCTGCTTGCGCAAGG
L643P For GCCACGGGAGCTGACCCTGGTGCCGACGGC
Rev GCCGTCGGCACCAGGGTCAGCTCCCGTGGC
V711M For CATGGCTACCGTTCTCCTGC
Rev CATGTCCTGGGCCTGCAC
S692G For GGGCACCTCGGAGGAGC
Rev CCAGCGGCGCCAGGAA
L624P For CCGTCCCGCGTTCGCT
Rev CGGGTGTGTGCCCAGGTT
L643P For GCCACGGGAGCTGACCCTGGTGCCG
Rev GCCGTCGGCACCAGGGTCAGCTCCC
Q115R For GTTGGTGGATGGACGGACACATCTGGTGCT
Rev AGCACCAGATGTGTCCGTCCATCCACCAAC
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